Sam Brusco, Associate Editor10.11.22
Sebia, a company providing screening and diagnostics solutions for oncology, metabolic diseases, genetic disorders, and autoimmune diseases, has acquired Zeus Scientific, an in vitro diagnostic (IVD) company that specializes in autoimmune and infectious diseases tech.
Zeus Scientific will expand Sebia’s autoimmunity capabilities and product portfolio, with a strong U.S. footprint. The deal’s financial terms were not disclosed.
“Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients,” Jean-Marc Chermette, Sebia’s president and CEO told the press. “Zeus Scientific has developed a strong expertise in autoimmunity and infectious diseases. There are many parallels in our respective R&D programs, as well as benefits for the development of our global commercial network. With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market. I am very pleased to welcome Zeus Scientific associates to the Sebia Group and look forward to a strong collaboration to accelerate innovation and global growth.”
Zeus Scientific’s clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology, and a number of infectious diseases, with a strong focus on Lyme disease.
“We are extremely pleased to join the Sebia team,” said Scott Tourville, CEO of Zeus Scientific. “Its world-leading position in clinical protein electrophoresis and in vitro diagnostic testing makes Sebia the ideal company to continue to build on Zeus Scientific’s 46-year legacy of diagnostic innovation.”
Zeus Scientific will expand Sebia’s autoimmunity capabilities and product portfolio, with a strong U.S. footprint. The deal’s financial terms were not disclosed.
“Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients,” Jean-Marc Chermette, Sebia’s president and CEO told the press. “Zeus Scientific has developed a strong expertise in autoimmunity and infectious diseases. There are many parallels in our respective R&D programs, as well as benefits for the development of our global commercial network. With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market. I am very pleased to welcome Zeus Scientific associates to the Sebia Group and look forward to a strong collaboration to accelerate innovation and global growth.”
Zeus Scientific’s clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology, and a number of infectious diseases, with a strong focus on Lyme disease.
“We are extremely pleased to join the Sebia team,” said Scott Tourville, CEO of Zeus Scientific. “Its world-leading position in clinical protein electrophoresis and in vitro diagnostic testing makes Sebia the ideal company to continue to build on Zeus Scientific’s 46-year legacy of diagnostic innovation.”